You are here: Industry Insights > melanoma

News List

Lack of Self-Exams Hampers Early Melanoma Identification drugs
January 19, 2020
The biggest obstacle to early detection and treatment of melanoma among residents of rural, frontier communities is a chronic lack of skin self-examination (SSE), according to a study recently published in Psychology, Health & Medicine.
Satisfaction High With Mohs Surgery for Melanoma In Situ drugs
January 17, 2020
Patients are very satisfied with Mohs micrographic surgery (MMS) for melanoma in situ, according to a research letter recently published in Dermatologic Surgery.
Weight-Loss Surgery Might Also Lower Skin Cancer Risk drugs
January 07, 2020
Weight-loss surgery does more than shed pounds: new research suggests it might also lower your risk for skin cancer. "This provides further evidence for a connection between obesity and malignant skin cancer ...
Genentech announces results of IMspire150 study in BRAF V600 mutation-positive advanced melanoma pharmaceutical-business-review
December 20, 2019
Genentech, a member of the Roche Group, announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma ...
Insurance Disparities ID'd in Diagnosis of Late-Stage Melanoma drugs
December 12, 2019
For nonelderly adults in the United States, having Medicaid or no health insurance is associated with increased odds of being diagnosed with late-stage melanoma compared with ...
Mohs Micrographic Surgery May Up Survival in Stage I Melanoma drugs
September 27, 2019
Mohs micrographic surgery (MMS) is associated with improved survival compared with traditional surgery with wide margin excision (WME) for stage I melanoma, according to a study published online in JAMA Dermatology.
2001 to 2016 Saw Large Increase in Mohs Surgery for Melanoma drugs
August 30, 2019
From 2001 to 2016, the use of Mohs surgery for melanoma increased more than threefold, according to a study published online in JAMA Dermatology.
Metastatic melanoma treatment gets Breakthrough Therapy Designation europeanpharmaceuticalreview
August 06, 2019
Breakthrough Therapy Designation has been granted for investigational agent bempegaldesleukin in combination with nivolumab.
FDA grants breakthrough status to new combination for melanoma pharmaceutical-technology
August 05, 2019
The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation for Nektar Therapeutics’ bempegaldesleukin (NKTR-214) in combination with Bristol-Myers Squibb (BMS)’s Opdivo (nivolumab) to treat melanoma.
Nektar Therapeutics, BMS Receive Breakthrough Therapy Designation contractpharma
August 02, 2019
Bempegaldesleukin in combination with Bristol-Myers Squibb's Opdivo aims to treat patients with untreated advanced melanoma.

Previous page 1 2 3 4 5 6 7 Next page